In the recent World Health Organization (WHO) Classification of Tumors of the Central Nervous System (2016), molecular genetic alterations have been incorporated to the classic histology of primary brain tumors (PBT) [1], including isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations and methylation of the O6-methylguanine-DNA methyltransferase promoter (MGMTp). This evidence concerns the gene IDH1 and brain neoplasm.